Arnaub Chatterjee, Datavant president and GM of life sciences, says the company will streamline data linking and evidence generation across real-world and clinical trial data.

The company will use the funds to move into the female health space and increase screening and preventive care.

The funds will be used to increase the development of GAIA-based Alzheimer's Disease drugs and widen the pipeline of blockbuster drug candidates.

The news comes alongside the U.S. Department of Defense’s announcement of $200 million contracts awarded to xAI, Anthropic, Google and OpenAI for AI implementation.

NEW YORK - At HIMSS AI Forum on Friday, during the talk, "The future of people centered care: earning (or losing) trust by leveraging AI and synthetic research," Dr. Adrienne Boissy, chief medical ...

The Focalist system aims to combine handheld robotics with real-time imaging to enable clinicians to place needles more ...

The organizations will co-develop AI playbooks, tools, a new certification program and best practices for health AI.

Phil, a company focused on pharmaceutical commercialization, has secured $60 million in growth debt financing from K2 HealthVentures. The company's PhilRx platform provides prescription services to ...

A new AI algorithm developed by researchers from the University of Western Australia has been found to better predict the ...

Apollo Hospitals is looking to spin off its digital health and pharmaceutical business as part of a strategic reorganisation. On 30 June, the company's board proposed to demerge the digital health and ...

The funds will be used to improve the company's flight cadence and expand its pharmaceutical lab capabilities.

Agentic AI offers the potential to streamline clinical workflows, but healthcare organizations must carefully assess its risks to ensure safe and effective implementation.